SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Opko Health, Inc. – ‘10-K’ for 12/31/19 – ‘EX-10.38’

On:  Monday, 3/2/20, at 5:29pm ET   ·   For:  12/31/19   ·   Accession #:  944809-20-7   ·   File #:  1-33528

Previous ‘10-K’:  ‘10-K’ on 3/1/19 for 12/31/18   ·   Next:  ‘10-K’ on 2/18/21 for 12/31/20   ·   Latest:  ‘10-K’ on 3/1/24 for 12/31/23   ·   1 Reference:  By:  Opko Health, Inc. – Next ‘10-K’ on 2/18/21 for 12/31/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/02/20  Opko Health, Inc.                 10-K       12/31/19  111:16M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.49M 
 2: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     39K 
 3: EX-10.36    Material Contract                                   HTML     60K 
 4: EX-10.37    Material Contract                                   HTML     50K 
 5: EX-10.38    Material Contract                                   HTML     65K 
 6: EX-21       Subsidiaries List                                   HTML     32K 
 7: EX-23.1     Consent of Experts or Counsel                       HTML     32K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     36K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     36K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     30K 
88: R1          Cover Page                                          HTML     92K 
24: R2          Consolidated Balance Sheets                         HTML    125K 
60: R3          Consolidated Balance Sheets (Parenthetical)         HTML     38K 
98: R4          Consolidated Statements of Operations               HTML     99K 
85: R5          Consolidated Statements of Comprehensive Loss       HTML     53K 
21: R6          Consolidated Statements of Equity                   HTML     89K 
59: R7          Consolidated Statements of Cash Flows               HTML    151K 
96: R8          Consolidated Statements of Cash Flows               HTML     31K 
                (Parenthetical)                                                  
89: R9          Business and Organization                           HTML     35K 
40: R10         Summary of Significant Accounting Policies          HTML     86K 
52: R11         Loss Per Share                                      HTML     36K 
108: R12         Investments                                         HTML     61K  
73: R13         Composition of Certain Financial Statement          HTML    216K 
                Captions                                                         
39: R14         Debt                                                HTML    135K 
51: R15         Shareholders' Equity                                HTML     40K 
107: R16         Accumulated Other Comprehensive Income (Loss)       HTML     50K  
72: R17         Equity-Based Compensation                           HTML     79K 
38: R18         Income Taxes                                        HTML    162K 
53: R19         Related Party Transactions                          HTML     49K 
91: R20         Employee Benefit Plans                              HTML     32K 
81: R21         Commitments and Contingencies                       HTML     47K 
18: R22         Revenue Recognition                                 HTML    118K 
55: R23         Strategic Alliances                                 HTML     55K 
90: R24         Leases                                              HTML    128K 
80: R25         Segments                                            HTML    140K 
17: R26         Fair Value Measurements                             HTML    111K 
54: R27         Derivative Contracts                                HTML     55K 
92: R28         Selected Quarterly Financial Data (Unaudited)       HTML     62K 
79: R29         Subsequent Events                                   HTML     34K 
74: R30         Summary of Significant Accounting Policies          HTML    148K 
                (Policies)                                                       
110: R31         Investments (Tables)                                HTML     51K  
49: R32         Composition of Certain Financial Statement          HTML    216K 
                Captions (Tables)                                                
36: R33         Debt (Tables)                                       HTML    101K 
76: R34         Accumulated Other Comprehensive Income (Loss)       HTML     50K 
                (Tables)                                                         
111: R35         Equity-Based Compensation (Tables)                  HTML     68K  
50: R36         Income Taxes (Tables)                               HTML    159K 
37: R37         Revenue Recognition (Tables)                        HTML     94K 
78: R38         Leases (Tables)                                     HTML    121K 
109: R39         Segments (Tables)                                   HTML    143K  
82: R40         Fair Value Measurements (Tables)                    HTML    110K 
94: R41         Derivative Contracts (Tables)                       HTML     57K 
63: R42         Selected Quarterly Financial Data (Unaudited)       HTML     62K 
                (Tables)                                                         
25: R43         Business and Organization (Details)                 HTML     30K 
83: R44         Summary of Significant Accounting Policies          HTML    141K 
                (Details)                                                        
95: R45         Loss Per Share - Narrative (Details)                HTML     42K 
64: R46         Investments - Accounting Method, Carrying Value     HTML     44K 
                and Underlying Equity in Net Assets of                           
                Unconsolidated Investments (Details)                             
26: R47         Investments - Narrative (Details)                   HTML    108K 
84: R48         Investments - Schedule of Net Gains and Losses on   HTML     35K 
                Equity Securities (Details)                                      
93: R49         Composition of Certain Financial Statement          HTML    190K 
                Captions (Details)                                               
101: R50         Composition of Certain Financial Statement          HTML     64K  
                Captions - Narrative (Details)                                   
67: R51         Composition of Certain Financial Statement          HTML     44K 
                Captions - Changes in Allowance for Doubtful                     
                Accounts, Provision for Inventory Reserve and Tax                
                Valuation (Details)                                              
35: R52         Composition of Certain Financial Statement          HTML     71K 
                Captions - Changes in Goodwill (Detail)                          
48: R53         Debt - Narrative (Details)                          HTML    244K 
100: R54         Debt - Schedule of Notes (Details)                  HTML     68K  
66: R55         Debt - Lines of Credit (Details)                    HTML     70K 
34: R56         Debt - Mortgage Notes and Other Debt (Details)      HTML     39K 
47: R57         Shareholders' Equity - Narrative (Details)          HTML     82K 
102: R58         Accumulated Other Comprehensive Income (Loss)       HTML     55K  
                (Details)                                                        
65: R59         Equity-Based Compensation - Narrative (Details)     HTML     82K 
23: R60         Equity-Based Compensation - Option-Pricing Formula  HTML     48K 
                (Details)                                                        
61: R61         Equity-Based Compensation - Summary of Option       HTML     85K 
                Activity (Details)                                               
99: R62         Income Taxes - Benefits (Provision) for Income      HTML     60K 
                Taxes (Details)                                                  
87: R63         Income Taxes - Deferred Income Taxes (Details)      HTML    103K 
22: R64         Income Taxes - Narrative (Details)                  HTML     66K 
58: R65         Income Taxes - Change in Gross Unrecognized Income  HTML     42K 
                (Details)                                                        
97: R66         Income Taxes - Difference in Federal and Effective  HTML     70K 
                Tax Rate (Details)                                               
86: R67         Income Taxes - Reconciliation Losses Before Tax,    HTML     36K 
                US and Foreign Jurisdictions (Details)                           
19: R68         Related Party Transactions - Narrative (Details)    HTML    261K 
62: R69         Employee Benefit Plans (Details)                    HTML     38K 
43: R70         Commitments and Contingencies (Details)             HTML     50K 
27: R71         Revenue Recognition - Narrative (Details)           HTML     62K 
68: R72         Revenue Recognition - Schedule of Disaggregation    HTML     49K 
                of Revenue (Details)                                             
103: R73         Revenue Recognition - Schedule of Product Sales     HTML     65K  
                Allowances and Accruals (Details)                                
46: R74         Strategic Alliances (Details)                       HTML    120K 
31: R75         Leases - Lease Assets and Liabilities (Details)     HTML     57K 
71: R76         Leases - Lease Liability Maturity (Details)         HTML     69K 
106: R77         Leases (Details)                                    HTML     36K  
41: R78         Leases - Supplemental Cash Flow Information         HTML     37K 
                (Details)                                                        
32: R79         Segments - Narrative (Details)                      HTML     39K 
44: R80         Segments - Operating Segments (Details)             HTML    116K 
29: R81         Segments - Reconciliation Property Plant and        HTML     40K 
                Equipment, US and Foreign Jurisdictions (Details)                
69: R82         Fair Value Measurements - Assets and Liabilities    HTML     64K 
                Measured at Fair Value (Details)                                 
104: R83         Fair Value Measurements - Carrying Amount and       HTML     40K  
                Estimated Fair Value of Long-Term Debt (Details)                 
45: R84         Fair Value Measurements - Level 3 Reconciliation    HTML     35K 
                (Details)                                                        
30: R85         Fair Value Measurements - Narrative (Details)       HTML     41K 
70: R86         Derivative Contracts - Fair Value and Presentation  HTML     44K 
                (Details)                                                        
105: R87         Derivative Contracts - Losses and Gains on          HTML     39K  
                Derivative Instruments (Details)                                 
42: R88         Selected Quarterly Financial Data (Unaudited)       HTML     45K 
                (Details)                                                        
33: R89         Subsequent Events (Details)                         HTML     58K 
77: R9999       Uncategorized Items - opk-12312019x10k.htm          HTML     35K 
57: XML         IDEA XML File -- Filing Summary                      XML    194K 
56: XML         XBRL Instance -- opk-12312019x10k_htm                XML   4.13M 
28: EXCEL       IDEA Workbook of Financial Reports                  XLSX    150K 
13: EX-101.CAL  XBRL Calculations -- opk-20191231_cal                XML    349K 
14: EX-101.DEF  XBRL Definitions -- opk-20191231_def                 XML   1.31M 
15: EX-101.LAB  XBRL Labels -- opk-20191231_lab                      XML   2.92M 
16: EX-101.PRE  XBRL Presentations -- opk-20191231_pre               XML   1.78M 
12: EX-101.SCH  XBRL Schema -- opk-20191231                          XSD    261K 
20: JSON        XBRL Instance as JSON Data -- MetaLinks              574±   835K 
75: ZIP         XBRL Zipped Folder -- 0000944809-20-000007-xbrl      Zip    652K 


‘EX-10.38’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  





OPKO HEALTH, INC.
CREDIT AGREEMENT
February 25, 2020


OPKO HEALTH, INC.
CREDIT AGREEMENT
This Credit Agreement (this "Agreement") is made as of the 25th day of February, 2020 by and among OPKO Health, Inc., a Delaware corporation (the "Company") and Frost Gamma Investments Trust, a Florida trust (the "Lender").
RECITAL
The Company desires to borrow from the Lender, and the Lender desires to loan to the Company up to an aggregate principal amount of $100,000,000 (the "Commitment"), pursuant to the terms set forth in this Agreement.
AGREEMENT
In consideration of the mutual promises contained herein and other good and valuable consideration, receipt of which is hereby acknowledged, the parties to this Agreement agree as follows:
1.Definitions.
As used in this Agreement, the following capitalized terms have the following meanings:
"Advance" means the amount of US Dollars advanced pursuant to this Agreement and as evidenced by the Note. "Affiliate" means, with respect to any Person, a Person that owns or controls directly or indirectly such Person, any Person that controls or is controlled by or is under common control with such Person, and each of that Person's senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person's managers and members;
"Agreement" means this Credit Agreement, as amended from time to time;
“Available Commitment” means, as of any date of determination, (a) the aggregate Commitment, as such amount may be reduced, changed or terminated in accordance with the terms of this Agreement, reduced by (b) the aggregate Advances outstanding on such date of determination.
"Business Day" means any day other than a day on which commercial banks in New York are required or permitted by law to be closed;
"Closing" means the closing of the issuance of the Note;
Commitment Fee” has the meaning set forth in Section 2.1 below;
"Common Stock" means the shares of common stock, $.01 par value, per share, of the Company;
"Company" has the meaning set forth in the introductory paragraph above;
"Event of Default" has the meaning set forth in Section 7 below;
Exchange Act” has the meaning set forth in Section 3.5 below;
"Material Adverse Effect" means a change or effect that is materially adverse to the financial condition, assets, or operations of the Company, or will prevent the transactions contemplated by this Agreement;
"Maturity Date" shall have the meaning set forth in the Note;
"Note" means the promissory note issued pursuant to this Agreement at the Closing, in substantially the form attached to this Agreement as Exhibit A;
"Person" shall mean and include any individual, partnership, corporation (including a business trust), joint stock company, limited liability company, unincorporated association, joint venture, governmental entity or other entity;
"Lender" has the meaning set forth in the introductory paragraph above; and
"Securities Act" means the Securities Act of 1933, as amended;
SEC” has the meaning set forth in Section 3.5 below; and
SEC Documents” has the meaning set forth in Section 3.5 below.
2.    Amount and Terms of Credit
2.1    Closing and Advances; Fees. (a) Subject to the terms and conditions of this Agreement and the Note, the Lender agrees to make advances (the “Advance(s)”) to the Company, from time to time from the date of this Agreement until the Maturity Date (as such terms are defined in the Note), at such times as the Company may request in writing. Each Advance, up to the Commitment, shall be in increments of $5,000,000. Each Advance to the Company shall be made on ten days prior written notice by the Company to the Lender at its address as set forth on the signature page herein. Subject to the terms and conditions of this Agreement and the Note, the Lender agrees to make any requested Advance to the Company on the date specified in the Advance notice.
(a)    The Company shall execute and deliver the Note to the Lender to evidence the Commitment and the Advances, dated the date hereof, and substantially in the form of Exhibit A hereto (the “Note”). The Note shall represent the obligation of the Company to pay the amount of the Commitment or, if less, the aggregate unpaid principal amount of all Advances made by the Lender to the Company. The date and amount of each Advance and any payment of principal with respect thereto shall be recorded by the Company on its books and in its records, and by the Lender on the grid portion of the Note.
3.    (c)     The Company agrees to pay to Lender a commitment fee, which shall accrue at 0.25% per annum (the “Commitment Fee”) on the average daily amount of the Available Commitment during the period from and including the date hereof to but excluding the date on which the Borrowing Commitment terminates. Accrued Commitment Fees shall be payable in arrears on the first day of each calendar month and on the date on which the Borrowing Commitment terminates, commencing on the first such date to occur after the date hereof. All Commitment Fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed, (including the first day but excluding the last day).Representations and Warranties of the Company.
The Company hereby represents and warrants to the Lender that:
3.1    Organization, Good Standing and Qualification.
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted or proposed to be conducted. The Company or its representatives are duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a Material Adverse Effect.
3.2    Authorization.
All corporate actions on the part of the Company, its officers, directors and stockholder necessary for (i) the authorization, execution and delivery of this Agreement and the Note, (ii) the performance of all obligations of the Company under this Agreement and the Note and (iii) the authorization, issuance and delivery of the Note have been taken or will be taken prior to the Closing, and this Agreement and the Note, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors' rights generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.
3.3    Compliance with Other Instruments; No Events of Default.
The Company is not in violation or default of any provisions of its Certificate of Incorporation, as amended, or Bylaws, as amended, or of any instrument, judgment, order, writ, or decree, or under any note, indenture, mortgage, lease, agreement, contract or purchase order to which it is a party or by which it is bound or of any provision of state or federal statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect. The execution, delivery and performance of this Agreement, the issuance of the Note and the consummation of the transactions contemplated hereby or thereby will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order, writ, decree or contract or an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company in either case which would have a Material Adverse Effect. No Event of Default shall have occurred or occur as a result of the Company's execution of this Agreement or the Note.
3.4    Disclosure.
The Company has made available to the Lender such information as the Lender has requested for deciding whether to acquire the Note.
3.5    Financial Statements.
As of the date hereof, the Company has filed all reports required to be filed by it under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d) thereof (as the “SEC Documents”) and has filed any such SEC Documents in a timely fashion. As of their respective dates, to the Company’s knowledge, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) promulgated thereunder, and to the best of the Company’s knowledge and belief, none of the SEC Documents, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. All material agreements to which the Company is a party or to which the property or assets of the Company are subject have been appropriately filed as exhibits to the SEC Documents as and to the extent required under the Exchange Act. The financial statements of the Company included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing, were prepared in accordance with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto, or, in the case of unaudited statements as permitted by Form 10-Q of the SEC), and fairly present in all material respects (subject in the case of unaudited statements, to normal, recurring audit adjustments unless otherwise disclosed) the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended. The Common Stock is traded on the Nasdaq Stock Exchange.
4.    Representations and Warranties of the Lender.
The Lender hereby represents and warrants to the Company that:
4.1    Authorization.
The Lender has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Lender, will constitute a valid and legally binding obligation of the Lender, enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors' rights generally, and as limited by laws relating to the availability of a specific performance, injunctive relief, or other equitable remedies.
4.2    Purchase Entirely for Own Account.
This Agreement is made with the Lender in reliance upon the Lender's representation to the Company, which by the Lender's execution of this Agreement, the Lender hereby confirms, that the Note to be acquired by the Lender will be acquired for investment for the Lender's own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Lender has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Lender further represents that the Lender does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Note.
4.3    Knowledge.
The Lender is aware of the Company's business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Note.
4.4    Restricted Securities.
The Lender understands that the Note has not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Lender's representations as expressed herein. The Lender understands that the Note is a "restricted security" under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Lender must hold the Note indefinitely unless it is registered with the Securities and Exchange Commission and qualified by state authorities or an exemption from such registration and qualification requirements is available. The Lender acknowledges that the Company has no obligation to register or qualify the Note for resale. The Lender further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Note, and on requirements relating to the Company which are outside of the Lender's control, and which the Company is under no obligation and may not be able to satisfy.
4.5    No Public Market.
The Lender understands that, except for the Common Stock, no public market now exists for any of the securities issued by the Company and the Company has made no assurances that a public market will ever exist for any of the Company's securities.
4.6    Accredited Investor.
The Lender is an accredited investor as defined in paragraphs (a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) of Rule 501(a) of Regulation D promulgated under the Securities Act.
5.    Conditions to the Lender's Obligations to make any Advance.
The obligation of the Lender to make an Advance under the Note is subject to the fulfillment of each of the following conditions, unless otherwise waived by the Lender:
5.1    Representations and Warranties.
The representations and warranties of the Company contained in Section 3 shall be true on and as of each applicable Advance with the same effect as though such representations and warranties had been made on and as of the date of such Advance;
5.2    Compliance with Agreements.
The Company shall have performed under and complied in all material respects with each agreement, covenant and obligation required by this Agreement to be so performed by or complied with by the Company on or before any Advance;
5.3    Consents.
The obtaining of all third party consents, approvals and waivers required for the Company to consummate the transactions contemplated by this Agreement;
5.4    Compliance with Laws.
Compliance by the Company with all applicable federal and state securities laws with respect to the issuance of the Note.
6.    Affirmative Covenants of the Company.
The Company will do all of the following for so long as the Note is outstanding:
6.1    Taxes.
Make timely payment of all material federal, state, and local taxes or assessments other than any taxes or assessments that the Company is contesting in good faith and deliver to the Lenders, on demand, appropriate certificates attesting to such payment.
6.2    Corporate Existence and Compliance with Laws.
Maintain its and its operating subsidiaries corporate existence and good standing under the laws of their state of incorporation and remain in good standing in each jurisdiction in which the failure to do so would have a Material Adverse Effect.
7.    Events of Default.
Any one of the following is an "Event of Default":
7.1    Payment Default.
If the Company fails to pay (i) any of the principal amount of and accrued interest on the Note on the Maturity Date, or (ii) any fees or interest related to the Note when due, and such failure to pay such fees or interest remains unremedied after the Company has received ten (10) Business Days prior written notice.
7.2    Covenant Default.
If the Company fails to perform any obligation under Section 6 and as to any default that can be cured, has failed to cure such default within thirty (30) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the thirty (30) day period or cannot after diligent attempts by the Company be cured within such thirty (30) day period, and such default is likely to be cured within a reasonable time, then the Company shall have an additional reasonable period (which shall not in any case exceed sixty (60) additional days) to attempt to cure such default, and within such reasonable time period the failure to have cured such default shall not be deemed an Event of Default;
7.3    Insolvency.
If the Company becomes insolvent or if the Company begins an insolvency proceeding or an insolvency proceeding is begun against the Company and not dismissed or stayed within ninety (90) days;
8.    Miscellaneous.
8.1    Successors and Assigns.
Subject to the limitations set forth herein, the Lender may assign this Agreement and the rights and obligations conferred hereby, in whole or in part upon the written consent of the Company. Any assignment made in violation of this Section 8.1 is null and void. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
8.2    Governing Law.
This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Florida, without giving effect to principles of conflicts of law.
8.3    Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.
8.4    Titles and Subtitles.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
8.5    Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile or electronic mail, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the party to be notified at such party's address or facsimile number as set forth below or as subsequently modified by written notice.
8.6    Amendments and Waivers.
Any term of this Agreement may be amended or waived only with the written consent of the Company and the holder of the Note.
8.7    Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith, in order to maintain the economic position enjoyed by each party as close as possible to that under the provision rendered unenforceable. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms.
8.8    Entire Agreement.
This Agreement, and the documents referred to herein constitute the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements existing between the parties hereto are expressly canceled.
8.9    Exculpation By Lender.
The Lender acknowledges that it is not relying upon any person, firm or corporation, other than the Company and its officers and directors, in making its investment or decision to invest in the Company.
[Signature Pages Follow]

The parties have executed this Credit Agreement as of the date first written above.

COMPANY:
OPKO HEALTH, INC.

By:
/s/ Steven D. Rubin    
Name: Steven D. Rubin        
Title: Executive Vice President of Administration

Address: 4400 Biscayne Blvd.            
     Miami, FL 33137    
    
LENDER:
FROST GAMMA INVESTMENTS TRUST

By:

Address: 4400 Biscayne Blvd.            
     Miami, FL 33137    
 


    

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/2/204
2/25/20
For Period end:12/31/194
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/18/21  Opko Health, Inc.                 10-K       12/31/20  111:16M
Top
Filing Submission 0000944809-20-000007   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 6:27:44.1am ET